ARIUS announces fourth quarter and year-end fiscal 2007 financi...( TORONTO Jan. 29 / ARIUS Research ...)

TORONTO, Jan. 29 /PRNewswire-FirstCall/ - ARIUS Research Inc., (TSX: ARI), a biotechnology company discovering and developing the next wave of antibody therapeutics, today announced its financial and operational results for the fourth quarter and fiscal year, ended November 30, 2007.

"Fiscal 2007 was a critical year in our development, highlighted by the significant advancement we made with the pre-IND programs for our lead drug candidates, our CD44 Cancer Stem Cell Program, our Trop-2 Signal Transduction Program, our CD59 Complement Inhibitor Program and our CD9 Cancer Stem Cell Program. The majority of our programs target cancer stem cells, an area that cancer researchers are particularly excited about as cancer stem cells have been implicated as the key cells responsible for the growth and spread of cancer," said Dr. David Young, President and CEO. "Building on this momentum, fiscal 2008 will be a pivotal year for us as we transition from a pre-clinical to a clinical company with the mission of moving one or more of our lead products into human clinical trials."

Program Updates:

CD44 Cancer Stem Cell Program

- Announced positive findings demonstrating no dose-limiting toxic

effects of ARIUS' lead therapeutic, ARH460-16-2, at doses up to

95 mg/kg in a dose-ranging pilot toxicology study in a non-human

primate model.

- Achieved significant and potent tumor growth inhibitory activity in

in vivo animal models of breast, prostate, liver, and AML cancers.

- Engaged the manufacturer Avid Bioservices to produce ARIUS' lead

anti-CD44 MAb under Current Good Manufacturing Practices ("cGMP") for

human clinical trials. Cell line producing the humanized anti-CD44

antibody was successfully transferred to Avid.

- Presented key data at AACR, ASCO, ASCO's Breast Cancer Symposium,

and AACR-EORTC.

- Met with FDA to discuss plans
'/>"/>